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Antimicrobial activity of Levofloxacin – M33 peptide conjugation 
or combination 
Federica Ceccherini,a Chiara Falciani,a Martina Onori,a Silvia Scali,b Simona Pollini,b Gian Maria 
Rossolini,b,c,d Luisa Braccib,e and Alessandro Pinib,e 
M33 is a branched peptide currently under preclinical characterization for development as a new drug against Gram-
negative bacteria. Here we report its antibacterial activity in conjugation or combination with levofloxacin (LVFX), a 
fluoroquinolone antibiotic. Antibacterial assays showed no significant differences in activity when used in conjugation, 
while the combination of M33 and LVFX showed improved activity against Gram-negative bacteria. Combination 
treatment therefore opposes antimicrobial-resistance, restoring the effect of LVFX. 
 
Introduction 
Antimicrobial resistance (AMR) is an increasing problem as bacteria 
become more offensive.1,2 It is therefore necessary to find new 
molecules with antimicrobial activity, new approaches and new 
applications of well-known compounds to fight infections. Several 
years ago, our research group identified, optimized and synthesized 
a tetra-branched peptide called M333,4,5 with good activity against 
Gram-negative bacteria: MICs against P. aeruginosa and K. 
pneumoniae are 1.5 µM.6,7 In the present study, we investigated 
M33 activity after covalent conjugation and after combination with 
levofloxacin (LVFX), a broad-spectrum fluoroquinolone antibiotic. 
We chose LVFX for two reasons: first, Gram-negative bacterial 
pathogens have already developed resistance to fluoroquinolones 
(FQ);8,9 second, LVFX only has one reactive moiety, a carboxylic 
group, that could be used orthogonally for solid-phase peptide 
synthesis (SPPS). Specifically, a lysine was linked to the C-terminus 
of the three-lysine-branched core, spaced with a beta-alanine, so 
that the side chain amine group could react with the LVFX 
carboxylic group. Unlike previous reports,10,11 this system enables 
complete SPPS and the conjugate is obtained by HPLC purification. 
This synthesis approach is favourable because it avoids 
intermediate purifications that could reduce the final yield. 
Repeated washing of resins eliminates impurities and excess 
reagents, producing a crude lyophilized solid ready for HPLC 
purification. Antimicrobial assays against P. aeruginosa and E. coli 
were carried out with free M33, M33-LVFX conjugate, M33 
combined with LVFX and free LVFX. The results showed that the 
activity of the conjugate was no better than that of M33, whereas 
the combination of the peptide with LVFX had a stronger effect 
than M33 and LVFX separately. These findings offer a good 
opportunity to fight AMR, restoring the activity of antibiotics 
currently challenged by AMR. 
Results and discussion 
M33-LVFX conjugate synthesis 
 
We designed a new approach to conjugating antibiotics with 
peptides using only the SPPS method. Specifically, we linked a well-
known antibiotic, LVFX, to M33 with the purpose of improving or 
restoring its activity against Gram-negative bacteria.12,13 LVFX 
structure is suitable for SPPS because it only has one carboxylic 
group as reactive moiety. LVFX was handled as an amino acid and 
added to the peptide in a further coupling step on the solid phase. 
The synthesis of M33-LVFX included steps in which certain amino 
acids were added manually, i.e. the first amino acid, Fmoc-Lys(Dde)-
OH, and the last one, Boc-Lys(Boc)-OH. The process then proceeded 
on the automatic synthesizer with Fmoc-βAla-OH as second step 
and two consecutive couplings of Fmoc-Lys(Fmoc)-OH to build the 
lysine core, followed by the nine sequential additions of Fmoc 
amino acids to complete the peptide KKIRVRLSA. At this point, the 
peptide, duly protected and still linked to the resin, was treated 
with hydrazine to append LVFX. Figure 1 illustrates the final steps of 
conjugation. The crude material was worked up as a mixture of free 
peptides. M33-LVFX was characterized by analytical RP-HPLC and 
MALDI-TOF (Figure 2 a,b).   
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This new synthesis method is favourable for many reasons. First, 
the process is run completely on resin in an automatic synthesizer 
with great saving of time. Besides, solid phase synthesis allows the  
excesses of reagents needed to obtain a good yield, removing them 
together with the product without wasting time or peptide. The 
synthesis process is therefore practical and quick, providing easily 
purified crude peptides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 b.  MS spectrum of M33-LVFX. 
 
Figure 1 i) Deprotection of lysine-Dde by 2% hydrazine in DMF; 10 min at room temperature;  ii) Conjugation of LVFX to M33 derivative; 
iii) Deprotection of side-chain groups and cleavage of conjugated peptide from resin. [(*) = side-chain protected amino acid] 
Figure 2 a.  HPLC profile of M33-LVFX from 60:40 A/B to 45:55 A/B 
in 40 minutes (A: TFA 0.1% in water; B: MeOH). 
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MIC assays on conjugation and combination of M33 with LVFX 
 
The M33-LVFX conjugate was tested for its antimicrobial activity in 
comparison with peptide M33, LVFX and the physical mixture of 
M33 with LVFX, against a collection of P. aeruginosa and E. coli 
strains with different susceptibilities to M33 and LVFX. The MICs 
obtained are shown in Table 1.  
The M33-LVFX conjugate showed MIC values that were on the 
whole similar to those of free M33. Altogether these results 
revealed that conjugation of M33 with LVFX did not affect the 
activity of M33 whereas it can impairthe activity of LVFX (E. coli 
ATCC 25922). M33 is effective against LVFX-resistant strain. 
 
Experimental Section 
Materials and methods 
All materials were obtained from commercial suppliers;  (Fmoc)4-
K2K-βAla-Wang Tentagel resin, Tentagel S Ram resin, Nα-9-
fluorenylmethoxycarbonyl (Fmoc) amino acids, O-(benzotriazol-1-
yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HBTU), 
trifluoroacetic acid (TFA) and piperidine were purchased from Iris 
Biotech GmbH and N,N-dimethylformamide (DMF), Methanol 
(MeOH) from Carlo Erba Reagents. N,N-diisopropylethylamine 
(DIPEA) was purchased from Merck SpA, Triisopropylsilane (TIS), 
Hydrazine and Levofloxacin from Sigma Aldrich. Milli-Q (Millipore) 
water was used for HPLC analysis. All coupling reactions were 
performed with 4 equivalents of amino acids  pre-activated  with 
HBTU (4 equiv), and DIPEA (8 equiv) in DMF. Coupling time was 
40min. The washing solvent  was DMF. Fmoc removal was  
performed with  40%  
 
40min. The washing solvent was DMF. Fmoc removal was  
performed with  40% piperidine in DMF (v/v) for 3 minutes and 20% 
piperidine in DMF for 20 minutes. Reaction volumes: a) for the 
180mg resin scale: 2.2ml for the condensation, 1.2ml for the 
deprotection, 2.5ml x 5 times washing and 2.5ml x 2 times for the 
cleavage; b) for the 30mg resin scale: 0.6ml for the condensation 
step, 0.6ml for the deprotection step, 1ml x 5 times washing and 
1ml x 2 for the cleavage. Peptides purification was performed  on  
Perkin Elmer HPLC  using a reverse phase C18 column  Jupiter 
Phenomenex  (10 μm 300 Å  250x10 mm) using  0.1% TFA in water 
(A) and MeOH (B) as mobile phase, with a 220 nm absorbance 
detection. For analytical RP-HPLC a C18 column  Jupiter 
Phenomenex  (5 μm 300 Å 250x0.46 mm) was used.  Purified 
peptides were characterized by UltraflexIII MALDI TOF/TOF mass 
spectrometry (Bruker Daltonics, Bremen, Germany). 
M33 synthesis 
M33 peptide was synthesized on (Fmoc)4-K2K-βAla-Wang Tentagel 
resin (loading 0.43 mmol/g, 180mg) and carried out on a Syro 
automated synthesizer (MultiSynTech, Germany). Resin swelling 
and washing was followed by removal of the Fmoc protecting 
groups. The resin was washed again and the first amino acid (Fmoc-
Ala-OH), preactivated with HBTU/DIPEA, was coupled for 40 
minutes under shaking to ensure complete anchoring. The resin was 
washed, followed by removal of the Fmoc group and washed again. 
The rest of the peptide chain was then synthesized with subsequent 
coupling reactions, washings, deprotections, and washing until the 
peptide was fully elongated. Side-chain-protecting groups were 
tert-butoxycarbonyl for Lys, 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl for Arg, and tert-butyl 
  MIC (µM) 
Species and strain Features M33 M33-LVFX 
conjugate 
Combination M33/LVFX a LVFX 
P. aeruginosa PT5 PAO1 (wild-type) 2.3 1.15 0.58 1.15 
P. aeruginosa PT629 MexAB-OprM overexpression 2.3 1.15 1.15 4.6 
P. aeruginosa PT149 MexEF-OprN overexpression 2.3 2.3 1.15 9.2 
E. coli ATCC 25922 Reference strain, 
fluoroquinolone susceptible 
2.3 2.3 0.04 0.04 
E. coli M6a fluoroquinolone resistant 0.58 1.15 0.58 >9.2 
E. coli V439a fluoroquinolone intermediate 2.3 2.3 1.15 4.6 
E. coli M103b fluoroquinolone susceptible 
(reduced susceptibility) 
0.58 0.58 0.58 0.58 
E. coli V386a fluoroquinolone resistant 0.58 2.3 1.15 >9.2 
Table 1 The strains tested included either wild-type or reference strains (indicated) or isolates f human origin with different susceptibility 
profiles to fluoroquinolones. Improvements with respect of single M33  and LVFX  is highlighted in grey. a M33 and LVFX were tested in 
equimolar amounts and the data refers to the minimum concentration of both that inhibited growth of the strain.   
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ether for Ser. Cleavage from the resin and removal of the side-chain 
protecting groups was accomplished simultaneously by treating the 
peptidyl-resin with the mixture TFA/H2O/TIS (95:2.5:2.5) for two 
hours. Then the resin was filtered off, and cold diethyl ether was 
added to the filtrate for peptide precipitation. The resulting peptide 
was purified by preparative RP-HPLC and then lyophilized. Yield: 
22,34 mg (6.2%). MS (MALDI TOF/TOF): M+ calculated for 
C209H399N75O45 is 4683.88 Da; found (m/z) is 4683.75 Da. HPLC 
method (analytic): 0.1% TFA in water (A) - MeOH (B), from 70:30 
A/B to 40:60 A/B in 30 minutes (r.t. 26.4min). 
Synthesis of M33-LVFX conjugate 
 
M33-LVFX conjugate was synthesized on Tentagel S Ram resin 
(loading 0.25 mmol/g, 30mg). Resin swelling and washing was 
followed by removal of the Fmoc protecting groups. Following the 
procedure described above for M33, Fmoc-Lys(Dde)-OH was 
introduced as first amino acid. The second amino acid added was 
Fmoc-βAla-OH, then Fmoc-Lys(Fmoc)-OH was added twice to build 
the lysine core. The rest of the peptide chain was synthesized with 
subsequent coupling reactions , washings, deprotections, and 
washings until the peptide was fully elongated. Finally Boc-
Lys(Boc)-OH was used as  N-terminals of the branched peptide. The 
Dde protecting group was then removed from N-ε of C-terminal 
lysine, by washing the peptidyl-resin with 2% hydrazine in DMF 
(v/v) (3x500μL). The free ε amino group was coupled with LVFX (75 
μmol; 10:1 LVFX:ε amino group) , activating the LVFX carboxylic 
group with HBTU (75 μmol) and DIPEA (150 μmol), overtnight. 
After draining and washing M33-LVFX conjugate was cleaved from 
the resin and deprotected, following the same procedure described 
for M33. Yield: 2.5 mg (6.5%). MS (MALDI TOF/TOF): M+ calculated 
for C233H430FN81O48 is 5154.42 Da; found is 5155.428 Da. HPLC 
method (analytic) 0.1% TFA in water (A) - MeOH (B), from 60:40 
A/B to 45:55 A/B in 40 minutes (r.t. 27.6 min). 
MIC assays 
 
MICs were determined using a standard microdilution assay as 
recommended by the Clinical and Laboratory Standards Institute.14 
Assays were performed in triplicate using cation-supplemented 
Mueller-Hinton (MH) broth (Becton Dickinson, Franklin Lakes, NJ, 
USA) and a bacterial inoculum of 5x104 CFU/well, in a final volume 
of 100 µl. Results were recorded after 18–20 h of incubation at 
37°C. Tested strains included the wild-type PT5 P. aeruginosa strain 
and its isogenic mutants PT629 and PT149 that overexpress efflux 
pumps MexAB–OprM and MexEF–OprN, respectively,15 and E. coli 
strains with different susceptibility profiles to fluoroquinolones.16 
 
Conclusions 
 
The need for innovative antimicrobial drugs is driving the search for 
new antibiotics or new strategies for antimicrobial therapy. We 
evaluated the use of the antimicrobial peptide M33, currently in 
preclinical development as a free compound, to improve the 
activity of LVFX against clinically relevant Gram-negative bacteria 
including LVFX-resistant strains. M33 was used in conjugation and in 
combination with LVFX. For the conjugation procedure we set up an 
original synthesis method, which can also be used for the 
conjugation of different peptides and small molecules. The results 
of the present study with resistant strains suggest that in this case a 
combination approach is more effective than conjugation for 
reinforcing antimicrobial therapy. Since many bacteria have already 
developed resistance to FQ, this finding indicates a possibility of 
recovering some of the antibiotics discarded due to AMR. 
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